These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 19948625)

  • 21. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study.
    Findling RL; Nyilas M; Forbes RA; McQuade RD; Jin N; Iwamoto T; Ivanova S; Carson WH; Chang K
    J Clin Psychiatry; 2009 Oct; 70(10):1441-51. PubMed ID: 19906348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
    J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study.
    Sachs G; Sanchez R; Marcus R; Stock E; McQuade R; Carson W; Abou-Gharbia N; Impellizzeri C; Kaplita S; Rollin L; Iwamoto T;
    J Psychopharmacol; 2006 Jul; 20(4):536-46. PubMed ID: 16401666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
    Findling RL; Robb A; Nyilas M; Forbes RA; Jin N; Ivanova S; Marcus R; McQuade RD; Iwamoto T; Carson WH
    Am J Psychiatry; 2008 Nov; 165(11):1432-41. PubMed ID: 18765484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical observation of aripiprazole in the treatment of autism].
    Xie Q; Tang J; Xu Y; Zeng HL
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Apr; 15(4):294-7. PubMed ID: 23607954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities.
    Valicenti-McDermott MR; Demb H
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):549-60. PubMed ID: 17069544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study.
    Vieta E; Owen R; Baudelet C; McQuade RD; Sanchez R; Marcus RN
    Curr Med Res Opin; 2010 Jun; 26(6):1485-96. PubMed ID: 20429835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
    McEvoy JP; Daniel DG; Carson WH; McQuade RD; Marcus RN
    J Psychiatr Res; 2007 Dec; 41(11):895-905. PubMed ID: 17631314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study.
    Vieta E; T'joen C; McQuade RD; Carson WH; Marcus RN; Sanchez R; Owen R; Nameche L
    Am J Psychiatry; 2008 Oct; 165(10):1316-25. PubMed ID: 18381903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Young mania rating scale line item analysis in pediatric subjects with bipolar I disorder treated with aripiprazole in a short-term, double-blind, randomized study.
    Mankoski R; Zhao J; Carson WH; Mathew SJ; Forbes RA
    J Child Adolesc Psychopharmacol; 2011 Aug; 21(4):359-64. PubMed ID: 21823911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial.
    Ghanizadeh A; Sahraeizadeh A; Berk M
    Child Psychiatry Hum Dev; 2014; 45(2):185-92. PubMed ID: 23801256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and tolerability of switching to aripiprazole from risperidone in subjects with autism spectrum disorders: a prospective open-label study.
    Ishitobi M; Kosaka H; Takahashi T; Yatuga C; Asano M; Tanaka Y; Ueno K; Okazaki R; Omori M; Hiratani M; Tomoda A; Wada Y
    Clin Neuropharmacol; 2013; 36(5):151-6. PubMed ID: 24045605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial.
    Ghaleiha A; Mohammadi E; Mohammadi MR; Farokhnia M; Modabbernia A; Yekehtaz H; Ashrafi M; Hassanzadeh E; Akhondzadeh S
    Paediatr Drugs; 2013 Dec; 15(6):505-14. PubMed ID: 23821414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
    Kwon JS; Jang JH; Kang DH; Yoo SY; Kim YK; Cho SJ;
    Psychiatry Clin Neurosci; 2009 Feb; 63(1):73-81. PubMed ID: 19154213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
    Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM
    J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months.
    Research Units on Pediatric Psychopharmacology Autism Network
    Am J Psychiatry; 2005 Jul; 162(7):1361-9. PubMed ID: 15994720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An open-label extension long-term study of the safety and efficacy of aripiprazole for irritability in children and adolescents with autistic disorder in Japan.
    Ichikawa H; Hiratani M; Yasuhara A; Tsujii N; Oshimo T; Ono H; Tadori Y
    Psychiatry Clin Neurosci; 2018 Feb; 72(2):84-94. PubMed ID: 28941259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risperidone in children with autism and serious behavioral problems.
    McCracken JT; McGough J; Shah B; Cronin P; Hong D; Aman MG; Arnold LE; Lindsay R; Nash P; Hollway J; McDougle CJ; Posey D; Swiezy N; Kohn A; Scahill L; Martin A; Koenig K; Volkmar F; Carroll D; Lancor A; Tierney E; Ghuman J; Gonzalez NM; Grados M; Vitiello B; Ritz L; Davies M; Robinson J; McMahon D;
    N Engl J Med; 2002 Aug; 347(5):314-21. PubMed ID: 12151468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.